2023-05-26 05:30:00 ET
When you think of Johnson & Johnson (NYSE: JNJ) , you may think of shampoo and Band-Aids. But those products are in J&J's consumer health business -- and they're not the company's biggest revenue drivers. In fact, J&J is in the process of spinning off that business into an entity called Kenvue.
What is J&J's top revenue driver? It's the company's pharmaceuticals business, which brought in more than $52 billion in sales last year. And the crown jewel of that business is immunology drug Stelara.
But that may not be for long. A key patent is set to expire this year -- and J&J recently settled a lawsuit allowing a challenger to soon enter the market. Here's what you need to know.
For further details see:
A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.